Several urged for increased education and awareness among healthcare providers to reduce stigma when treating HIV patients in ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Dr. Colleen Kelley, principal investigator for PURPOSE 2, emphasized the jab's effectiveness, "When compared to the background HIV incidence... lenacapavir reduced HIV infections by 96%." She added, ...

Rep. Barbara Lee reflects on the progress and importance of Black women in office, what her mentor Shirley Chisholm would ...